Multivalent nanoparticles activate T-dependent antibody response via antigen presentation by both B cells and dendritic cells
Xuejing Ma, Chang Guo, Runhan Li, Zhiyu Gao, Penghui Ma, Wenjun Wang, Keyan Bao, Xueli Zhang, Han Wang, Ping Zhu, George Fu Gao, Mingzhao Zhu, Zhaolin Hua, Baidong Hou
Journal:Cell Reports
IF:7.7
DOI:10.1016/j.celrep.2026.117332
PMID:42085184
Published:2026-05-04
research field:疫苗学细胞生物学免疫学纳米医学
Abstract
Multivalent nanoparticle vaccines elicit potent T cell-dependent (TD) antibody responses, yet how they initiate CD4 + T cell help remains unclear. Here, we show that antigen-specific B cells function as antigen-presenting cells (APCs) for CD4 + T cell priming across distinct nanoparticle platforms, including AP205 and ferritin. Using SARS-CoV-2 RBD and mpox virus A35 antigens, we demonstrate that B cells and dendritic cells (DCs) act redundantly to initiate early CD4 + T cell activation. In hosts lacking MHC class II expression on non-B cells, B cells alone were sufficient to drive naive CD4 + T cell proliferation. Moreover, B cell-mediated antigen presentation was required for inducing TD responses beyond the draining lymph nodes. These findings reveal a general mechanism by which multivalent nanoparticles engage B cells as APCs and highlight a potential strategy to enhance vaccine-induced immunity.
本文使用的Yeasen产品


